Ellen Frankel
Procedural Dermatology · Cranston, RINPI 1053306423
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,643 of the $173,199 with a category attached, or 71.4%. 34 manufacturers reported payments, led by AbbVie at 33.5% of the total. Reporting peaked in 2019 at $103,819 and has fallen 99.8% since, to $171 in 2023.
Across 762 payments — averaging $227.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$58K
- Amgen$30K
- Bristol Myers Squibb$29K
- Pfizer$24K
- Aclaris Therapeutics, Inc.$6K
- Sun Pharmaceutical Industries Inc.$6K
- plus $20K from 28 others
Across 861 payments — averaging $3628.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$667K
- UCB SA$604K
- Amgen$588K
- AbbVie$404K
- Sun Pharmaceutical Industries Inc.$146K
- Janssen Research & Development, LLC$145K
- plus $571K from 14 others
What the payments were for
- Consulting fees$13,0088%
- Speaking & faculty fees$123,64371%
- Travel & lodging$19,16511%
- Food & beverage$17,37010%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $57,938 |
| Amgen | 72 | $30,218 |
| Bristol Myers Squibb | 38 | $29,375 |
| Pfizer | 62 | $23,642 |
| Aclaris Therapeutics, Inc. | 17 | $6,262 |
| Sun Pharmaceutical Industries Inc. | 37 | $5,804 |
| UCB Biosciences Inc. | 31 | $5,104 |
| Almirall LLC | 9 | $3,667 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,560 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 100 | $2,260 |
| UCB, Inc. | 35 | $1,125 |
| LEO Pharma Inc. | 66 | $879 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $763 |
| Novartis | 21 | $340 |
| Incyte Corporation | 9 | $337 |
| VYNE Pharmaceuticals Inc. | 5 | $232 |
| Galderma Laboratories, L.p. | 6 | $222 |
| Regeneron Healthcare Solutions, Inc. | 3 | $188 |
| Dermira, Inc. | 6 | $154 |
| Sanofi | 7 | $144 |
| Prugen, Inc. Pharmaceuticals | 1 | $124 |
| Lilly USA, LLC | 6 | $121 |
| Merz North America, Inc. | 1 | $104 |
| Kyowa Kirin, Inc. | 5 | $103 |
| Biofrontera Inc. | 3 | $95 |
| Johnson & Johnson | 6 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Mayne Pharma Commercial LLC | 3 | $61 |
| Stemline Therapeutics Inc. | 1 | $57 |
| Janssen Scientific Affairs, LLC | 3 | $51 |
| Genentech USA, Inc. | 3 | $49 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| EPI Health, LLC | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few procedural dermatology providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Other procedural dermatology in Cranston
- Robert LeonardCranston$420
- Seth FederCranston$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.